CSIMarket
 


Scpharmaceuticals Inc   (SCPH)
Other Ticker:  
 
 

SCPH's Income from Cont. Operations Growth by Quarter and Year

Scpharmaceuticals Inc 's Income from Cont. Operations results by quarter and year




SCPH Income from Cont. Operations (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -7.32 -7.78 -10.82
III Quarter September -10.16 -6.55 -9.04 -6.21
II Quarter June -9.70 -7.06 -8.30 -7.26
I Quarter March -7.73 -7.10 -7.09 -8.72
FY   -27.59 -28.03 -32.21 -33.01



SCPH Income from Cont. Operations third quarter 2022 Y/Y Growth Comment
Scpharmaceuticals Inc in the third quarter 2022 recorded loss from continued operations of $ -10.16 millions.

According to the results reported in the third quarter 2022, Scpharmaceuticals Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Scpharmaceuticals Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the third quarter 2022.




SCPH Income from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Scpharmaceuticals Inc 's third quarter 2022 Income from Cont. Operations $ -10.16 millions SCPH's Income Statement
Scpharmaceuticals Inc 's third quarter 2021 Income from Cont. Operations $ -6.55 millions Quarterly SCPH's Income Statement
New: More SCPH's historic Income from Cont. Operations Growth >>


SCPH Income from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Scpharmaceuticals Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SCPH's III. Quarter Q/Q Income from Cont. Operations Comment
III. Quarter 2022 accomplishment of -10.16 millions by Scpharmaceuticals Inc come out even less good considering the loss from continued operations -9.70 millions in the previous quarter.

Within Major Pharmaceutical Preparations industry Scpharmaceuticals Inc achieved highest sequential Income from Cont. Operations growth. While Scpharmaceuticals Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


SCPH's III. Quarter Q/Q Income from Cont. Operations Comment
III. Quarter 2022 loss from continued operations of -10.16 millions by Scpharmaceuticals Inc come out even worse considering the -9.70 millions loss from continued operations a quarter before.

Within Major Pharmaceutical Preparations industry Scpharmaceuticals Inc achieved highest sequential Income from Cont. Operations growth. While Scpharmaceuticals Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Scpharmaceuticals Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Income from Cont. Operations 12 Months Ending $ -34.91 $ -31.30 $ -28.66 $ -28.03 $ -28.50
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Scpharmaceuticals Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -35 millions in the Sep 30 2022 period.
The situation is detiriorating as the cumulative loss from continued operations is becoming larger from $ -31.3 millions in the twelve months ending a quarter before and $ -9.7 millions from the TTM period ending Sep 30 2021.

Scpharmaceuticals Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Scpharmaceuticals Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -35 millions in the Sep 30 2022 period.
The results are getting worse as the cumulative loss from continued operations is getting bigger from $ -31.3 millions in the twelve months ending a quarter before and $ -9.7 millions for the twelve months ending in the quarter a year ago Avani Venkatesan  mentioned.

Scpharmaceuticals Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
SCPH's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for SCPH's Competitors
Income from Cont. Operations Growth for Scpharmaceuticals Inc 's Suppliers
Income from Cont. Operations Growth for SCPH's Customers

You may also want to know
SCPH's Annual Growth Rates SCPH's Profitability Ratios SCPH's Asset Turnover Ratio SCPH's Dividend Growth
SCPH's Roe SCPH's Valuation Ratios SCPH's Financial Strength Ratios SCPH's Dividend Payout Ratio
SCPH's Roa SCPH's Inventory Turnover Ratio SCPH's Growth Rates SCPH's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2022
Abiomed Inc 86.35%$ 86.352 millions
Stryker Corp86.30%$ 86.301 millions
Universal Security Instruments Inc86.27%$ 86.267 millions
American Shared Hospital Services83.33%$ 83.333 millions
Vir Biotechnology Inc 58.76%$ 58.757 millions
United Therapeutics Corporation47.08%$ 47.081 millions
Dexcom Inc 42.74%$ 42.736 millions
Pro dex Inc 42.14%$ 42.140 millions
Medpace Holdings Inc 35.93%$ 35.931 millions
Zimmer Biomet Holdings Inc 33.20%$ 33.196 millions
Iradimed Corporation33.03%$ 33.026 millions
Eli Lilly And Company30.77%$ 30.772 millions
Bio techne Corp30.09%$ 30.085 millions
Merit Medical Systems Inc27.62%$ 27.618 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

FOUR's Profile

Stock Price

FOUR's Financials

Business Description

Fundamentals

Charts & Quotes

FOUR's News

Suppliers

FOUR's Competitors

Customers & Markets

Economic Indicators

FOUR's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071